Regrow Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -8.46%
- Ebitda -8.46%
- Net Worth -14.67%
- Total Assets -38.75%
About Regrow Therapeutics
Regrow Therapeutics Private Limited (RTPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 September 2017 (Seven years and five months 20 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Yash Sanghavi and Satyen Sanghavi serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U36999MH2017PTC299383
- Company No.
299383
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Sep 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Regrow Therapeutics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyen Sanghavi  | Director | 05-Sep-2017 | Current |
| Yash Sanghavi | Director | 05-Sep-2017 | Current |
Financial Performance of Regrow Therapeutics.
Regrow Therapeutics Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 8.46% decrease in profit. The company's net worth observed a substantial decline by a decrease of 14.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Regrow Therapeutics?
In 2022, Regrow Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Regrow Biosciences Private LimitedYash Sanghavi and Satyen Sanghavi are mutual person
Satyan Pharmaceuticals Private LimitedYash Sanghavi and Satyen Sanghavi are mutual person
- Biocord Lifescience Private Limited
Yash Sanghavi and Satyen Sanghavi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Regrow Therapeutics?
Unlock and access historical data on people associated with Regrow Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Regrow Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Regrow Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
